Research programme: RNA interference-based cancer therapeutics - Marina Biotech

Drug Profile

Research programme: RNA interference-based cancer therapeutics - Marina Biotech

Alternative Names: Debio 1141; MDR-09513; MDR-09521; MRNA-046

Latest Information Update: 22 May 2015

Price : $50

At a glance

  • Originator MDRNA
  • Developer AstraZeneca China; Debiopharm Group; Marina Biotech
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Hepatocellular carcinoma; Malignant ascites
  • No development reported Urogenital cancer

Most Recent Events

  • 23 Apr 2015 Marina Biotech receives patent allowance for DILA2 technology in Japan, Israel and Europe
  • 25 Feb 2015 Marina Biotech has patent protection for DiLA2 technology in USA, Europe, Japan, China and Australia
  • 27 Aug 2013 No development reported for Urogenital cancer in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top